DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Tremelimumab is an investigational drug.
There have been 154 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and M.D. Anderson Cancer Center.
There are ninety-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Tremelimumab
|Immunotherapy for Advanced Liver Cancer||Mirror Biologics, Inc.||Phase 2/Phase 3|
|Immunotherapy for Advanced Liver Cancer||Immunovative Therapies, Ltd.||Phase 2/Phase 3|
|Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)||University of Alabama at Birmingham||Phase 1/Phase 2|
Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tremelimumab||⤷ Try it Free||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||⤷ Try it Free|
|Tremelimumab||⤷ Try it Free||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||⤷ Try it Free|
|Tremelimumab||⤷ Try it Free||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tremelimumab||Argentina||AR102536||2034-11-05||⤷ Try it Free|
|Tremelimumab||Australia||AU2015342940||2034-11-05||⤷ Try it Free|
|Tremelimumab||Brazil||BR112017008568||2034-11-05||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|